Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Amryt Pharma
Amryt Pharma
(AMYT)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Annual sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Lojuxta
Lomitapide
2013-07-31
2025-2027
Hypercholesterolemia
Myalepta
Metreleptin
2018-07-29
Lipodystrophy
,
Familial partial lipodystrophy
Mycapssa
Octreotide
2022-12-02
2029-2040
Pancreatic neoplasms
,
Diarrhea
,
Pituitary neoplasms
,
Adenoma
,
Acromegaly
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Lomitapide
healthy volunteers/patients
,
hyperlipidemias
,
hypercholesterolemia
,
hyperlipoproteinemia type ii
,
homozygous familial hypercholesterolemia
,
atherosclerosis
,
pregnancy
Metreleptin
type 1 diabetes mellitus
,
obesity
,
body weight
,
non-alcoholic fatty liver disease
,
fatty liver
,
overweight
,
metabolic syndrome
,
liver diseases
,
hiv infections
,
syndrome
,
fasting
,
amenorrhea
,
lipoma
,
multiple symmetrical lipomatosis
,
lipomatosis
,
anorexia
,
anorexia nervosa
,
diabetes mellitus
,
familial partial lipodystrophy
,
hyperlipidemias
,
insulin resistance
,
lipodystrophy
,
congenital generalized lipodystrophy
,
morbid obesity
,
hiv-associated lipodystrophy syndrome
,
hypertriglyceridemia
,
weight loss
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use